{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T08:44:44Z","timestamp":1790844284850,"version":"4.1.0"},"reference-count":37,"publisher":"American Society of Hematology","issue":"14","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,7,22]]},"abstract":"<jats:sec>\n                  <jats:title>Abstract<\/jats:title>\n                  <jats:p>Patients with chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) have seen significant treatment advancements with the emergence of Bruton tyrosine kinase inhibitors like ibrutinib. Statin use has been linked to reduced mortality in several cancers, including CLL. However, their concomitant use with targeted therapies such as ibrutinib remains unexplored. This study investigates the association of statin use with survival and adverse event outcomes in patients with CLL\/SLL initiating contemporary treatment regimens, including ibrutinib. Individual participant data from 4 randomized trials\u2014RESONATE, RESONATE-2, iLLUMINATE, and HELIOS\u2014were used. Associations between baseline statin use and treatment outcomes were examined using Cox proportional hazards models for overall survival (OS), progression-free survival (PFS), and cancer-specific survival (CCS), and logistic regression models for grade \u22653 adverse effects. Analyses were adjusted for age, sex, weight, Eastern Cooperative Oncology Group performance status, disease diagnosis, bulky disease (\u22655 cm), time since diagnosis, comorbidity count, and the use of beta-blockers, calcium channel blockers, angiotensin-converting enzyme inhibitors\/angiotensin receptor blockers, and diuretics. Of 1467 patients, 424 (29%) were using statins. Statin use was significantly associated with improved OS (adjusted hazard ratio [aHR] 0.62 [95% CI, 0.48\u20110.79], P &amp;lt; 0.001), PFS (aHR 0.74 [95% CI, 0.62-0.89], P = 0.001), and CCS (aHR 0.39 [95% CI, 0.22\u20130.70], P = 0.001). Findings were consistent across ibrutinib vs nonibrutinib treatment arms and CLL vs SLL diagnosis. No significant association with grade \u22653 adverse effects was observed. Statin use was identified as an independent positive prognostic factor in patients with CLL\/SLL, irrespective of the treatment employed. Further research is needed to validate these results and explore the underlying impacts of statins in CLL\/SLL. These trials were registered at www.ClinicalTrials.gov as #NCT01578707, #NCT01722487, #NCT02264574, and #NCT01611090.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1182\/bloodadvances.2024015287","type":"journal-article","created":{"date-parts":[[2025,4,23]],"date-time":"2025-04-23T09:51:50Z","timestamp":1745401910000},"page":"3566-3575","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":7,"title":["Statin use and survival in CLL\/SLL treated with ibrutinib: pooled analysis of 4 randomized controlled trials"],"prefix":"10.1182","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4182-065X","authenticated-orcid":false,"given":"Ahmad Y.","family":"Abuhelwa","sequence":"first","affiliation":[{"name":"1Department of Pharmacy Practice and Pharmacotherapeutics, University of Sharjah, Sharjah, United Arab Emirates"},{"name":"2Research Institute of Medical and Health Sciences, University of Sharjah, Sharjah, United Arab Emirates"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-4944-7055","authenticated-orcid":false,"given":"Sara A.","family":"Almansour","sequence":"additional","affiliation":[{"name":"1Department of Pharmacy Practice and Pharmacotherapeutics, University of Sharjah, Sharjah, United Arab Emirates"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2040-4961","authenticated-orcid":false,"given":"Jennifer R.","family":"Brown","sequence":"additional","affiliation":[{"name":"3Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA"},{"name":"4Department of Medicine, Harvard Medical School, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Humaid O.","family":"Al-Shamsi","sequence":"additional","affiliation":[{"name":"5Department of Oncology, Burjeel Cancer Institute, Burjeel Medical City, Abu Dhabi, United Arab Emirates"},{"name":"6Emirates Oncology Society, Dubai, United Arab Emirates"},{"name":"7College of Medicine, Ras Al Khaimah Medical and Health Sciences, Ras Al Khaimah, United Arab Emirates"},{"name":"8Gulf Cancer Society, Alsafa, Kuwait"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0031-7150","authenticated-orcid":false,"given":"Ziad","family":"Abuhelwa","sequence":"additional","affiliation":[{"name":"9Department of Hematology and Medical Oncology, University of South Florida\/H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8012-684X","authenticated-orcid":false,"given":"Zelal","family":"Kharaba","sequence":"additional","affiliation":[{"name":"1Department of Pharmacy Practice and Pharmacotherapeutics, University of Sharjah, Sharjah, United Arab Emirates"},{"name":"2Research Institute of Medical and Health Sciences, University of Sharjah, Sharjah, United Arab Emirates"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasser","family":"Bustanji","sequence":"additional","affiliation":[{"name":"10Department of Clinical Sciences, University of Sharjah, Sharjah, United Arab Emirates"},{"name":"11Department of Biopharmaceutics and Clinical Pharmacy, the University of Jordan, Amman, Jordan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad H.","family":"Semreen","sequence":"additional","affiliation":[{"name":"2Research Institute of Medical and Health Sciences, University of Sharjah, Sharjah, United Arab Emirates"},{"name":"12Department of Medicinal Chemistry, University of Sharjah, Sharjah, United Arab Emirates"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-6377-4745","authenticated-orcid":false,"given":"Salma","family":"Ali","sequence":"additional","affiliation":[{"name":"1Department of Pharmacy Practice and Pharmacotherapeutics, University of Sharjah, Sharjah, United Arab Emirates"},{"name":"2Research Institute of Medical and Health Sciences, University of Sharjah, Sharjah, United Arab Emirates"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4669-0233","authenticated-orcid":false,"given":"Ahmad","family":"Alhuraiji","sequence":"additional","affiliation":[{"name":"13Department of Haematology, Kuwait Cancer Control Center, Kuwait City, Kuwait"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3725-793X","authenticated-orcid":false,"given":"Ross A.","family":"McKinnon","sequence":"additional","affiliation":[{"name":"14College of Medicine and Public Health, Flinders University, Bedford Park, SA, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1999-866X","authenticated-orcid":false,"given":"Michael J.","family":"Sorich","sequence":"additional","affiliation":[{"name":"14College of Medicine and Public Health, Flinders University, Bedford Park, SA, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karem H.","family":"Alzoubi","sequence":"additional","affiliation":[{"name":"1Department of Pharmacy Practice and Pharmacotherapeutics, University of Sharjah, Sharjah, United Arab Emirates"},{"name":"2Research Institute of Medical and Health Sciences, University of Sharjah, Sharjah, United Arab Emirates"},{"name":"15Department of Clinical Pharmacy, Faculty of Pharmacy, Jordan University of Science and Technology, Irbid, Jordan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashley M.","family":"Hopkins","sequence":"additional","affiliation":[{"name":"14College of Medicine and Public Health, Flinders University, Bedford Park, SA, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2025,7,11]]},"reference":[{"issue":"7","key":"2025072208563312300_bib1","doi-asserted-by":"crossref","first-page":"1827","DOI":"10.1002\/cncr.26474","article-title":"Hematologist\/oncologist disease-specific expertise and survival: lessons from chronic lymphocytic leukemia (CLL)\/small lymphocytic lymphoma (SLL)","volume":"118","author":"Shanafelt","year":"2012","journal-title":"Cancer"},{"issue":"4","key":"2025072208563312300_bib2","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1159\/000510768","article-title":"Current treatment of refractory\/relapsed chronic lymphocytic leukemia: a focus on novel drugs","volume":"144","author":"Smolewski","year":"2021","journal-title":"Acta Haematol"},{"issue":"11","key":"2025072208563312300_bib3","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1038\/s41571-019-0239-8","article-title":"Chronic lymphocytic leukaemia: from genetics to treatment","volume":"16","author":"Bosch","year":"2019","journal-title":"Nat Rev Clin Oncol"},{"issue":"2","key":"2025072208563312300_bib4","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1007\/s00432-021-03625-3","article-title":"Interactions in cancer treatment considering cancer therapy, concomitant medications, food, herbal medicine and other supplements","volume":"148","author":"Wolf","year":"2021","journal-title":"J Cancer Res Clin Oncol"},{"issue":"2","key":"2025072208563312300_bib5","doi-asserted-by":"crossref","first-page":"151","DOI":"10.3390\/ph15020151","article-title":"Beyond lipid-lowering: effects of statins on cardiovascular and cerebrovascular diseases and cancer","volume":"15","author":"Morofuji","year":"2022","journal-title":"Pharmaceuticals"},{"key":"2025072208563312300_bib6","doi-asserted-by":"crossref","first-page":"1188926","DOI":"10.3389\/fphar.2023.1188926","article-title":"New insights into the therapeutic potentials of statins in cancer","volume":"14","author":"Liu","year":"2023","journal-title":"Front Pharmacol"},{"issue":"15","key":"2025072208563312300_bib7","doi-asserted-by":"crossref","first-page":"3948","DOI":"10.3390\/cancers15153948","article-title":"Statins in cancer prevention and therapy","volume":"15","author":"Ricco","year":"2023","journal-title":"Cancers"},{"issue":"3","key":"2025072208563312300_bib8","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1016\/j.critrevonc.2013.07.011","article-title":"Targeting inflammatory pathways in chronic lymphocytic leukemia","volume":"88","author":"Rozovski","year":"2013","journal-title":"Crit Rev Oncol Hematol"},{"issue":"6","key":"2025072208563312300_bib9","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1002\/ijc.30185","article-title":"Impact of statin use on cancer recurrence and mortality in breast cancer: a systematic review and meta-analysis","volume":"139","author":"Manthravadi","year":"2016","journal-title":"Int J Cancer"},{"issue":"22","key":"2025072208563312300_bib10","doi-asserted-by":"crossref","first-page":"4142","DOI":"10.1002\/cncr.33797","article-title":"Association of statin use with clinical outcomes in patients with triple-negative breast cancer","volume":"127","author":"Nowakowska","year":"2021","journal-title":"Cancer"},{"issue":"1","key":"2025072208563312300_bib11","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1038\/s41392-021-00572-w","article-title":"Small molecules in targeted cancer therapy: advances, challenges, and future perspectives","volume":"6","author":"Zhong","year":"2021","journal-title":"Signal Transduct Target Ther"},{"issue":"12","key":"2025072208563312300_bib12","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1002\/ajh.25638","article-title":"Final analysis from RESONATE: Up to six years of follow-up on ibrutinib in patients with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma","volume":"94","author":"Munir","year":"2019","journal-title":"Am J Hematol"},{"issue":"11","key":"2025072208563312300_bib13","doi-asserted-by":"crossref","first-page":"3440","DOI":"10.1182\/bloodadvances.2021006434","article-title":"Up to 8-year follow-up from RESONATE-2: first-line ibrutinib treatment for patients with chronic lymphocytic leukemia","volume":"6","author":"Barr","year":"2022","journal-title":"Blood Adv"},{"issue":"9","key":"2025072208563312300_bib14","doi-asserted-by":"crossref","first-page":"2108","DOI":"10.3324\/haematol.2021.279012","article-title":"First-line treatment of chronic lymphocytic leukemia with ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab: final analysis of the randomized, phase III iLLUMINATE trial","volume":"107","author":"Moreno","year":"2022","journal-title":"Haematologica"},{"issue":"13","key":"2025072208563312300_bib15","doi-asserted-by":"crossref","first-page":"3188","DOI":"10.1080\/10428194.2020.1795159","article-title":"Final 5-year findings from the phase 3 HELIOS study of ibrutinib plus bendamustine and rituximab in patients with relapsed\/refractory chronic lymphocytic leukemia\/small lymphocytic lymphoma","volume":"61","author":"Fraser","year":"2020","journal-title":"Leuk Lymphoma"},{"issue":"3","key":"2025072208563312300_bib16","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/djw226","article-title":"The association of dyslipidemia with chronic lymphocytic leukemia: a population-based study","volume":"109","author":"Mozessohn","year":"2017","journal-title":"J Natl Cancer Inst"},{"issue":"9","key":"2025072208563312300_bib17","doi-asserted-by":"crossref","first-page":"1424","DOI":"10.1182\/blood-2013-07-517102","article-title":"Statin and aspirin use is associated with improved outcome of FCR therapy in relapsed\/refractory chronic lymphocytic leukemia","volume":"123","author":"Chae","year":"2014","journal-title":"Blood"},{"issue":"9","key":"2025072208563312300_bib18","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1158\/1055-9965.EPI-19-0107","article-title":"Statin use and chronic lymphocytic leukemia incidence: a nested case\u2013control study in Manitoba, Canada","volume":"28","author":"Righolt","year":"2019","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"22","key":"2025072208563312300_bib19","doi-asserted-by":"crossref","first-page":"2344","DOI":"10.1182\/blood.V114.22.2344.2344","article-title":"Influence of statin therapy on the clinical course of chronic lymphocytic leukemia","volume":"114","author":"Friedman","year":"2009","journal-title":"Blood"},{"issue":"4","key":"2025072208563312300_bib20","doi-asserted-by":"crossref","first-page":"797","DOI":"10.3109\/10428194.2015.1088651","article-title":"A link between hypercholesterolemia and chronic lymphocytic leukemia","volume":"57","author":"Chow","year":"2016","journal-title":"Leuk Lymphoma"},{"issue":"12","key":"2025072208563312300_bib21","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.3109\/10428194.2010.520050","article-title":"Statin use and need for therapy in chronic lymphocytic leukemia","volume":"51","author":"Friedman","year":"2010","journal-title":"Leuk Lymphoma"},{"issue":"7","key":"2025072208563312300_bib22","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.3109\/10428194.2010.486877","article-title":"Statin and non-steroidal anti-inflammatory drug use in relation to clinical outcome among patients with Rai stage 0 chronic lymphocytic leukemia","volume":"51","author":"Shanafelt","year":"2010","journal-title":"Leuk Lymphoma"},{"issue":"5","key":"2025072208563312300_bib23","doi-asserted-by":"crossref","first-page":"554","DOI":"10.4103\/2230-8210.163106","article-title":"Pleiotropic effects of statins","volume":"19","author":"Kavalipati","year":"2015","journal-title":"Indian J Endocrinol Metab"},{"issue":"12","key":"2025072208563312300_bib24","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1038\/s41569-018-0098-5","article-title":"Safety and efficacy of statin therapy","volume":"15","author":"Adhyaru","year":"2018","journal-title":"Nat Rev Cardiol"},{"issue":"5","key":"2025072208563312300_bib25","doi-asserted-by":"crossref","first-page":"692","DOI":"10.21037\/tlcr.2019.09.08","article-title":"Current perspectives on statins as potential anti-cancer therapeutics: clinical outcomes and underlying molecular mechanisms","volume":"8","author":"Fatehi Hassanabad","year":"2019","journal-title":"Transl Lung Cancer Res"},{"issue":"1","key":"2025072208563312300_bib26","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.canlet.2012.04.011","article-title":"Statins and cancer: current and future prospects","volume":"324","author":"Osmak","year":"2012","journal-title":"Cancer Lett"},{"key":"2025072208563312300_bib27","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1186\/s13046-021-02041-2","article-title":"Statins: a repurposed drug to fight cancer","volume":"40","author":"Jiang","year":"2021","journal-title":"J Exp Clin Cancer Res"},{"issue":"9","key":"2025072208563312300_bib28","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1016\/S0301-472X(03)00192-9","article-title":"Simvastatin induces apoptosis of B-CLL cells by activation of mitochondrial caspase 9","volume":"31","author":"Chapman-Shimshoni","year":"2003","journal-title":"Exp Hematol"},{"issue":"7","key":"2025072208563312300_bib29","doi-asserted-by":"crossref","first-page":"799","DOI":"10.3390\/metabo13070799","article-title":"The role of cholesterol in chronic lymphocytic leukemia development and pathogenesis","volume":"13","author":"White","year":"2023","journal-title":"Metabolites"},{"issue":"8","key":"2025072208563312300_bib30","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1016\/S0022-2275(20)41954-6","article-title":"In vivo regulation of human leukocyte 3-hydroxy-3-methylglutaryl coenzyme A reductase: increased enzyme protein concentration and catalytic efficiency in human leukemia and lymphoma","volume":"32","author":"Harwood","year":"1991","journal-title":"J lipid Res"},{"key":"2025072208563312300_bib31","doi-asserted-by":"crossref","first-page":"114654","DOI":"10.1016\/j.bcp.2021.114654","article-title":"Lipoproteins and cancer: the role of HDL-C, LDL-C, and cholesterol-lowering drugs","volume":"196","author":"Patel","year":"2022","journal-title":"Biochem Pharmacol"},{"issue":"1","key":"2025072208563312300_bib32","doi-asserted-by":"crossref","first-page":"22153","DOI":"10.1038\/s41598-020-78315-0","article-title":"Systems biology drug screening identifies statins as enhancers of current therapies in chronic lymphocytic leukemia","volume":"10","author":"Gimenez","year":"2020","journal-title":"Sci Rep"},{"issue":"2","key":"2025072208563312300_bib33","doi-asserted-by":"crossref","first-page":"e38","DOI":"10.1161\/ATV.0000000000000073","article-title":"Statin safety and associated adverse events: a scientific statement from the American Heart Association","volume":"39","author":"Newman","year":"2019","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"3","key":"2025072208563312300_bib34","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1177\/2042098612439884","article-title":"Safety of statins: an update","volume":"3","author":"Hu","year":"2012","journal-title":"Ther Adv Drug Saf"},{"issue":"6","key":"2025072208563312300_bib35","doi-asserted-by":"crossref","first-page":"373","DOI":"10.2165\/0129784-200808060-00004","article-title":"Statin adverse effects: a review of the literature and evidence for a mitochondrial mechanism","volume":"8","author":"Golomb","year":"2008","journal-title":"Am J Cardiovasc Drugs"},{"issue":"6","key":"2025072208563312300_bib36","first-page":"631","article-title":"Statin therapy: review of safety and potential side effects","volume":"32","author":"Ramkumar","year":"2016","journal-title":"Acta Cardiol Sin"},{"issue":"12","key":"2025072208563312300_bib37","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1007\/s00228-020-02967-0","article-title":"Efficacy and safety profile of statins in patients with cancer: a systematic review of randomised controlled trials","volume":"76","author":"Thomas","year":"2020","journal-title":"Eur J Clin Pharmacol"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/9\/14\/3566\/2402653\/blooda_adv-2024-015287-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/9\/14\/3566\/2402653\/blooda_adv-2024-015287-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,22]],"date-time":"2025-07-22T12:56:43Z","timestamp":1753189003000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/9\/14\/3566\/536859\/Statin-use-and-survival-in-CLL-SLL-treated-with"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,11]]},"references-count":37,"journal-issue":{"issue":"14","published-print":{"date-parts":[[2025,7,22]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2024015287","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,7,22]]},"published":{"date-parts":[[2025,7,11]]}}}